Írsko - angličtina - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - clarithromycin lactobionate - powder for concentrate for solution for infusion - 500 milligram(s) - clarithromycin

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals ltd - clarithromycin; clarithromycin - powder for concentrate for solution for infusion - 500 milligram(s) - macrolides; clarithromycin

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

amdipharm limited - clarithromycin - powder for concentrate for solution for infusion - 500 milligram(s) - macrolides; clarithromycin

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

apotex nz ltd - clarithromycin 250mg; clarithromycin 250mg - film coated tablet - 250 mg - active: clarithromycin 250mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose iron oxide yellow macrogol 8000 magnesium stearate microcrystalline cellulose titanium dioxide active: clarithromycin 250mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose iron oxide yellow macrogol 8000 magnesium stearate microcrystalline cellulose titanium dioxide - clarithromycin is indicated for treatment of infections caused by susceptible organisms. such infections include: 1. respiratory tract infections including bronchitis, pneumonia, tonsillitis, sinusitis and pharyngitis. 2. skin and soft tissue infections such as folliculitis, cellulitis and erysipelas. 3. disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localized infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii. 4. prevention of disseminated mycobacterium avium complex infection in hiv-infected patients with cd4 lymphocyte counts less than or equal to 100/mm3.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

apotex nz ltd - clarithromycin 500mg; clarithromycin 500mg - film coated tablet - 500 mg - active: clarithromycin 500mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose iron oxide yellow macrogol 8000 magnesium stearate microcrystalline cellulose titanium dioxide active: clarithromycin 500mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose iron oxide yellow macrogol 8000 magnesium stearate microcrystalline cellulose titanium dioxide - clarithromycin is indicated for treatment of infections caused by susceptible organisms. such infections include: 1. respiratory tract infections including bronchitis, pneumonia, tonsillitis, sinusitis and pharyngitis. 2. skin and soft tissue infections such as folliculitis, cellulitis and erysipelas. 3. disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localized infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii. 4. prevention of disseminated mycobacterium avium complex infection in hiv-infected patients with cd4 lymphocyte counts less than or equal to 100/mm3.

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - clarithromycin - pdr/conc/soln for infus - 500 milligram(s) - macrolides; clarithromycin

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - clarithromycin, quantity: 500 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; colloidal anhydrous silica; croscarmellose sodium; macrogol 4000; hypromellose; titanium dioxide; microcrystalline cellulose; powdered cellulose - clarithromycin sandoz clarithromycin is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: acute streptococcal pharyngitis; community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophilia and streptococcus pneumoniae;uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes;disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other anti mycobacterial agents.prevention of disseminated mycobacterium avium complex infection in hiv infected adults with cd4 lymphocyte counts <75 cells/mm 3 (see precautions). disseminated infection due to mycobacterium avium complex should be excluded by a negative blood culture prior to commencement of prophylaxis.acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae;combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection. clarithromycin sandoz clarithromycin is indicated for use in children for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro organisms in the conditions listed below:acute streptococcal pharyngitis and tonsillitis caused by streptococcus pyogenes; community acquired pneumonia including infections due to chlamydia pneumoniae, mycoplasma pneumoniae and legionella pneumophila; skin and skin structure infections (eg impetigo); disseminated or localised infections due to mycobacterium avium or mycobacterium intracellulare in immunocompromised children, including those with hiv infection or aids. acute otitis media.note:1. penicillins are the drug of first choice in the treatment of acute otitis media. 2. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections including prophylaxis of rheumatic fever. clarithromycin appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx, however substantial data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present. 3. there is insufficient evidence of efficacy to support the use of clarithromycin in acute bronchitis in young children. 4. the data presented on infections of skin and skin structure were confined largely to mild to moderate infections such as impetigo.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - clarithromycin, quantity: 250 mg - tablet, film coated - excipient ingredients: titanium dioxide; powdered cellulose; magnesium stearate; hypromellose; macrogol 4000; croscarmellose sodium; microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate - clarithromycin sandoz clarithromycin is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: acute streptococcal pharyngitis; community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophilia and streptococcus pneumoniae;uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes;disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other anti mycobacterial agents.prevention of disseminated mycobacterium avium complex infection in hiv infected adults with cd4 lymphocyte counts <75 cells/mm 3 (see precautions). disseminated infection due to mycobacterium avium complex should be excluded by a negative blood culture prior to commencement of prophylaxis.acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae;combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection. clarithromycin sandoz clarithromycin is indicated for use in children for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro organisms in the conditions listed below:acute streptococcal pharyngitis and tonsillitis caused by streptococcus pyogenes; community acquired pneumonia including infections due to chlamydia pneumoniae, mycoplasma pneumoniae and legionella pneumophila; skin and skin structure infections (eg impetigo); disseminated or localised infections due to mycobacterium avium or mycobacterium intracellulare in immunocompromised children, including those with hiv infection or aids. acute otitis media.note:1. penicillins are the drug of first choice in the treatment of acute otitis media. 2. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections including prophylaxis of rheumatic fever. clarithromycin appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx, however substantial data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present. 3. there is insufficient evidence of efficacy to support the use of clarithromycin in acute bronchitis in young children. 4. the data presented on infections of skin and skin structure were confined largely to mild to moderate infections such as impetigo.

Spojené štáty - angličtina - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 250 mg - clarithromycin tablets usp are indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below: pharyngitis/tonsillitis due to streptococcus pyogenes (the usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. clarithromycin is generally effective in the eradication of s. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present). acute maxillary sinusitis due to haemophilus influenzae , moraxella catarrhalis , or streptococcus pneumoniae . acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae . community-acquired pneumonia due to haemophilus influenzae , mycoplasma pneum

Spojené štáty - angličtina - NLM (National Library of Medicine)

actavis pharma, inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin extended-release tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, haemophilus parainfluenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin extended-release tablets (in adults) are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin extended-release tablets are indicated [see indications and usage (1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: - haemophilus influenzae (in adults) - haemophilus parainfluenzae (in adults) - moraxella catarrhalis (in adults) - mycoplasma pneumoniae, streptococcus pneumoniae , chlamydophila pneumoniae (in adults) clarithromycin extended-release tablets are indicated only for acute maxillary